Chiral Thiazole Compound for Selective PPARδ Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PPARδ ligands lack selectivity and efficacy in activating the PPARδ receptor, with existing compounds only achieving 30-40% of total ligand-binding activity and having reduced selectivity to PPARα and PPARγ subtypes.
Innovation Solution
The development of an optical-active thiazole compound represented by formula 1, which is a selective PPARδ activator, prepared through a multi-step synthesis process involving Grignard reactions, metal substitutions, and nucleophilic introductions, with the R-form isomer demonstrating high selectivity and activity, while the S-form shows reduced activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PPARδ ligands are used, then some PPARδ activity is achieved (30-40% of total ligand-binding activity), but selectivity to PPARδ is reduced and cytotoxicity increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure parameters of PPARδ ligands, specifically developing optical-active thiazole compounds with specific molecular configurations. The R-form isomer of the thiazole compound achieves high PPARδ selectivity with an EC50 of 0.6 nM while significantly reducing cytotoxicity compared to existing ligands. This structural parameter optimization resolves the contradiction between achieving sufficient PPARδ activity and minimizing harmful effects.
2Reliability
If existing PPARδ ligands are used, then partial PPARδ activation is achieved, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent improves therapeutic efficacy by changing the ligand binding activity parameter through development of the R-form thiazole compound, which achieves complete PPARδ activation with an EC50 of 0.6 nM. This represents a significant improvement over existing ligands that only achieve 30-40% activation, thereby resolving the contradiction between partial activation and sufficient therapeutic effect.
3Adaptability or versatility
If non-selective PPAR ligands are used, then broad PPAR subtype coverage is achieved, but specific PPARδ activation is reduced
Solution Approach 1:
The patent applies asymmetry by developing optical-active (chiral) thiazole compounds where the R-form isomer specifically activates PPARδ. The chiral center creates asymmetric molecular structure that provides high selectivity for PPARδ over other PPAR subtypes. This asymmetric design resolves the contradiction between broad subtype coverage and specific PPARδ activation by enabling selective targeting through molecular handedness.
Data Source
AI summary
The present invention relates to a thiazole compound as a peroxisome proliferator activated receptor δ (PPARδ) activator or pharmaceutically acceptable salts thereof, and a pharmaceutical composition, a functional cosmetic composition, a health food, health beverages, a food additive and animal feeds containing the same.